Palvella Therapeutics
PVLA
90 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 6 closing their positions.
400% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 6
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
37% more capital invested
Capital invested by funds: $130M → $179M (+$48.6M)
36% more funds holding
Funds holding: 66 → 90 (+24)
0.02% more ownership
Funds ownership: 0.64% → 0.66% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
83% less call options, than puts
Call options by funds: $27K | Put options by funds: $156K
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.59M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$1.7M |
| 3 |
Millennium Management
New York
|
+$1.49M |
| 4 |
Renaissance Technologies
New York
|
+$1.47M |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$1.22M |
Top Sellers
PVLA Hedge Fund Activity: Q4 2017 in Review
90 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2017, worth a combined $179M — up 37% from $130M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PVLA positions and 6 closed out — a net gain of 24 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $2.59M. The largest seller was Tekla Capital Management, cutting an estimated $5.09M.
- 90 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2017, up from 66 in Q3 2017.
- Funds reported $179M of Palvella Therapeutics stock for Q4 2017, up 37% quarter-over-quarter.
- 30 funds opened new Palvella Therapeutics positions in Q4 2017 and 6 closed out, a net change of +24 holders.
- The largest Palvella Therapeutics buyer in Q4 2017 was Arrowstreet Capital, an estimated $2.59M added.
- The largest Palvella Therapeutics seller in Q4 2017 was Tekla Capital Management, an estimated $5.09M sold.
Based on aggregated 13F filings for Q4 2017.